Eikon pulls in $351M as lead drug begins Phase III journey

Eikon Therapeutics Secures $351M Funding for Cancer Drug Development Eikon Therapeutics raised $351 million in a Series D funding round124 Total funding raised since 2019 launch now exceeds $1.1 billion1 Lead drug EIK1001 has entered Phase III trials for advanced melanoma14 Clinical studies ongoing in 28 countries across 5 continents14 ## Pipeline Highlights: EIK1001: TLR7/8 […]

Eikon pulls in $351M as lead drugs begins Phase III journey

Eikon Therapeutics Secures $350.7 Million Series D to Advance Cancer Drug Pipeline Eikon Therapeutics, a pivotal-stage biotechnology company, has raised $350.7 million in a Series D financing round to support its clinical-stage programs and future pipeline development147. This significant funding brings Eikon’s total capital raised since its founding in 2019 to over $1.1 billion17. ## […]

AI-Guided Cardiac Ablation Outperforms Standard Treatment for Persistent Atrial Fibrillation

Volta Medical, artificial intelligence, cardiac ablation, atrial fibrillation, TAILORED-AF trial, pulmonary vein isolation, electrophysiology

Fourth Patient Receives Gene-Edited Pig Kidney in Groundbreaking Clinical Trial

xenotransplantation, clinical trial, gene-edited pig kidney, FDA approval, United Therapeutics, eGenesis, end-stage renal disease, organ shortage